Eisai To Resubmit Aricept Severe Alzheimer’s sNDA In December
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is considering changing from paper to electronic filing to resolve formatting issues behind FDA’s refusal to file the sNDA.
You may also be interested in...
Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says
National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.
Alzheimer’s Drugs Should Be Limited To Moderate Disease, U.K.’s NICE Says
National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.
Eisai Resubmits Aricept sNDA For Severe Alzheimer’s
Eisai has submitted a reformatted electronic supplemental new drug application for Aricept (donepezil), the firm announced Dec. 19